Compare Lithium Americas Corp (LAC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Novo Nordisk A/S — how do they compare? Lithium Americas Corp trades at $2.36 (market cap $850.38M), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 194.4× Lithium Americas Corp's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Novo Nordisk A/S for 116 Days on average.
| LAC | NVO | |
|---|---|---|
Market Cap | $850.38M | $165.31B |
Volume | 8,804,637 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $63.98 |
52-Week Low | $2.36 | $35.29 |
Typical Hold Time | 27 Days | 116 Days |
Enterprise Value | $1.19B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.28% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten EPS estimates in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
Investment outlook balances development potential against current losses. The consensus price target of $4.00 suggests 70% upside, but execution risks and lithium price volatility remain concerns. Construction progress at Thacker Pass could drive rerating, though the stock faces near-term pressure from negative cash flow and market skepticism.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
